The FDA is moving away from requiring animal models for investigational new drug (IND) applications for new monoclonal ...

A special congressional committee has recommended a $15 billion investment to boost the United States' biotech advantage over ...

CEO Emma Walmsley said the company has been anticipating tariffs on the industry and is “confident” the company can navigate through it, Ashleigh Furlong and Ruth David of Bloomberg reports. The U.S.

India’s pharmaceutical market grew 8.4% in FY25, led by strong value growth in cardiac, gastrointestinal, and anti-diabetic therapies, according to Pharmarack.

Computerized prompts recommending standard-spectrum empiric antibiotics for low-risk patients in the hospital with either ...